ROMA or death: Advances in epithelial ovarian cancer diagnosis

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 3, 2011, Pages 443-445

  Plebani, Mario ^a   Melichar, Bohuslav ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CA 125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEIN;

ALGORITHM; CANCER MORTALITY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EPITHELIUM TUMOR; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952778180     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.073     Document Type: Review

References (17)

1. Ozols RF. Systematic therapy for ovarian cancer: Current status and new treatments. Semin Oncol 2006;33:S3-11.
2. Bast RC Jr, Feeney M, Lazarus H. Reactivity of a monoclonal antibody with human ovarian carcinoma J Clin Invest 1981;68: 1331-7. (Pubitemid 12235035)
3. Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
4. Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. (Pubitemid 34178440)
5. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: Roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205-19. (Pubitemid 350061148)
6. Kirchhoff C, Osterhoff C, Habben I, Ivell R. Cloning and analysis of mRNA expressed specifically in the human epididymis. Int J Androl 1990;13:155-67. (Pubitemid 20116937)
7. Schaner ME, Ross DT, Ciavarino G. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86. (Pubitemid 37444641)
8. Hellstrom I, Raycraft J, Hayde-Ledbetter M. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700. (Pubitemid 36793054)
9. Scholler N, Lowe KA, Bergan LA. Use of yeast-secreted in vivo biotinylated recombinanat antibodies (biobodies) in beadbased ELISA. Clin Cancer Res 2008;14:2647-55.
10. Li J, Dowdy S, Tipton T, Podratz K, Lu W-G, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-66.
11. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2007;108:402-8. (Pubitemid 351174295)
12. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
13. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100:1315-9.
14. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:228.e1-5.
15. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati G, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: Is it really useful? Clin Chem Lab Med 2011;49:521-5.
16. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: A prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34.
17. Grolund B. Høgdall C, Hilden J, Engelholm SA, Høgdall EVS, Hansen HH. Should CA125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8. (Pubitemid 41199651)